Market Overview

Oncothyreon Plunges On Drug Fail; Wedbush Slashes Price Target

Related ONTY
Events for the Week of Sept. 8-12
Morning Market Losers

Oncothyreon (NASDAQ: ONTY) plunged Tuesday after the company's tecemotide lung cancer treatment failed to show any effects in a trial in Japan.

Merck KGaA has exclusive rights to develop and commercialize the drug and informed Oncothyreon it would discontinue the Phase I/II study.

Tecemontide is one of four drugs in Oncothyreon's pipeline and Wedbush's Gregory Wade said the lack of tecemotide results in Japan raises doubts about the company's ONT-10 cancer drug.

Both tecemotide and ONT-10 stimulate the immune system to recognize and attack cells that express MUC1, a protein found on non-small cell lung, breast, colon, kidney, ovarian, pancreatic and prostate cancers.

ONT-10 is currently being evaluated in Phase I clinical trials in patients with solid tumors.

Wade maintained an Outperform rating on Oncothyreon, but cut his target from $6 to $3 per share.

Oncothyreon traded recently at $2.26, down 18.7 percent.

Latest Ratings for ONTY

DateFirmActionFromTo
Mar 2014Canaccord GenuityDowngradesBuyHold
Mar 2014Stifel NicolausMaintainsBuy
Jun 2013WedbushMaintainsOutperform

View More Analyst Ratings for ONTY
View the Latest Analyst Ratings

Posted-In: Gregory Wade WedbushAnalyst Color News Price Target FDA Analyst Ratings

 

Related Articles (ONTY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters